Almac Expands Asia Pacific Operations, Establishes Regional Operations Centre in Singapore
Almac has announced the expansion of its clinical services and technologies capabilities to include on-the-ground leadership as well as technical, project and operational resources in Asia. The company has established regional hubs in Singapore and Japan to better enable the industry’s growing need to conduct clinical trials in Asia and/or manage global trials from the region. Local teams apply insights gained from Almac’s experience managing more than 10,000 trials around the world to design, implement and manage drug supply strategies and efficient technology solutions throughout the life of the study.
“From protocol to patient to kit destruction, Almac delivers high quality, flexible and cost-effective solutions that enable a more comprehensive approach to trial supply management,” says Alan Armstrong, CEO, Almac. “No one else can provide the global scale, scope and reach required to optimise sponsors’ R&D investments across every facet of the supply chain — within Asia or around the world.”
Providing expert and responsive service is essential for all trials, but particularly those managed from or within Asia. Sponsors must be able to navigate technical, logistical and clinical complexities from trial start-up through to supply and patient management.
Almac’s local teams support studies of all sizes and degrees of complexity, helping sponsors to achieve time-saving efficiencies, reduce costs and improve trial outcomes. Services are augmented by a secure, web-based interface to monitor trial execution anywhere in the world, multi-lingual technical and project teams, and an in-house 24 x 7 x 365 hotline connecting site staff to on-call clinicians and unblinding specialists. By positioning operational resources within the same time zones as where trials are executed, Almac is able to resolve issues in less than 24 hours — which in turn eliminates communications delays and improves patient care.
Almac is strengthening its Asia Pacific offerings by establishing a new secondary packaging facility in Singapore that will open by the end of 2014. Through this facility, the company will better enable just-in-time supply management and support drug pooling strategies, which further optimise the supply chain, minimise wastage and reduce costs.
“With 15% of all clinical trials conducted in Asia, it’s imperative that we provide localised service and support to our clients,” continues Armstrong. “We’ve long managed clinical trials on a global basis, but there’s now sufficient critical mass that requires we establish dedicated resources in the region. I’m pleased that our international expertise and global capabilities are now even more accessible to sponsors in this critically-important part of the world, and look forward to opening our new packaging facility later this year.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance